glp 1 receptor agonist drugs The New GLP-1 Receptor Agonists: The New
Description
2016, Sun et al
Lillys CEO Dave Ricks warned that the growth of compounding could create a backdoor generic world. This article is exclusive to STAT+ subscribers Unlock this article plus daily coverage and analysis of the pharma industry by subscribing to STAT+
Almdal TP, Heindorff H, Bardram L, Vilstrup H
Gallego-Colon, W
They are not claims of treatment, clinical effectiveness or suitability for personal use
